Navigation Links
MR spectroscopy identifies breast cancer, reduces biopsies
Date:9/24/2007

OAK BROOK, Ill.Proton magnetic resonance spectroscopy (H MRS) used in conjunction with magnetic resonance imaging (MRI) can aid radiologists in diagnosing breast cancer while reducing the number of false-positive results and invasive biopsies, according to a study focusing on non-mass enhancing breast lesions. The study, conducted at Memorial Sloan-Kettering Cancer Center in New York City, appears in the October issue of the journal Radiology.

All of the cancers present in this study were identified with MR spectroscopy, said the studys lead author, Lia Bartella, M.D., director of breast imaging at Eastside Diagnostic Imaging in New York City.

The American Cancer Society estimates that 212,920 women will be diagnosed with breast cancer in the United States this year. MRI is playing an increasingly important role in the screening of women at high risk for breast cancer. However, while MRI depicts more abnormal findings than other breast screening procedures, it is not 100 percent accurate in distinguishing benign from malignant lesions, resulting in a large number of breast biopsy procedures recommended on the basis of imaging findings. Currently, approximately 80 percent of breast lesions biopsied are found to be benign.

Non-mass enhancing lesions are characterized by enhancement of an area that is not a mass or lump and may extend over large or small regions. Non-mass lesions occur with benign hormonal changes, but can also signify malignancy. Biopsy is often required to distinguish benign non-mass lesions from cancer.

With MR spectroscopy, which adds only 10 minutes to a standard MRI exam, the radiologist is able to see the chemical make-up of a tumor. In most cases, the results indicate whether or not the lesion is cancerous without the need for biopsy.

Non-mass enhancing lesions frequently pose a dilemma to the radiologist when evaluating the breast for the presence of cancer, especially in premenopausal women, Dr. Bartella said. Potentially, the use of proton MR spectroscopy may help decrease the number of benign biopsies for non-mass enhancing lesions.

For the study, Dr. Bartella and colleagues performed H MRS on 32 non-mass enhancing breast lesions in 32 women, age 20 to 63. Twenty-five of the patients had lesions that had been labeled suspicious at MRI.

H MRS can provide radiologists with chemical information about a lesion by measuring the levels of choline compounds, which are markers of an active tumor. In the study, positive choline findings were present in 15 of 32 lesions, including all 12 cancers, giving H MRS a specificity of 85 percent and a sensitivity of 100 percent. If only the lesions with positive choline findings had been biopsied, 17 (68 percent) of 25 lesions may have been spared invasive biopsies and none of the cancers would have been missed.

By performing MR spectroscopy of the suspicious lesion after an MRI scan, we can noninvasively see which tumors show elevated choline levels and are likely malignant, Dr. Bartella said. This chemical information added to the information provided by MRI can eliminate the need for biopsy to find out what the lesion is made of.

Dr. Bartella hopes that in the future, MR spectroscopy will be incorporated into routine diagnostic breast MRI procedures, significantly decreasing the need for needle biopsies.


'/>"/>

Contact: Linda Brooks
media@rsna.org
630-590-7762
Radiological Society of North America
Source:Eurekalert

Related medicine news :

1. Nuclear magnetic resonance spectroscopy aids in mapping protein structure
2. Preterm Babies Benefited from a New NI Spectroscopy
3. A New Form of Spectroscopy to Assess Reproductive Potential of Embryo
4. Research identifies trigger that sets of Huntingtons disease
5. Research Identifies The Causes Of Snoring
6. New Test Identifies Candidates For Cardiac Defibrillator
7. Research Identifies Osteoporosis Controlling Protein
8. New Technique Identifies Unknown Genetic Mutations That Can Cause Cancer
9. Study Identifies Mechanism Which May Help Tamoxifen Work Better
10. 3-D Ultrasound Identifies Women at Risk for Impending Preterm Birth
11. Novel Test Identifies Leukemia Patients Likely to Respond to New Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... A study by the founder of ... colleague, Sudeep Roy, MD, was recently published in the American Journal of Cosmetic ... details Drs. Buckingham and Roy’s study on the use of Electro Lube during the ...
(Date:3/27/2017)... ... March 27, 2017 , ... Buzzies parent company, The TouchPoint ... Rent the Runway Foundation and UBS’ Project Entrepreneur. Mayo will present her pitch about ... , Project Entrepreneur’s second annual venture competition ignites bold ideas by providing women ...
(Date:3/27/2017)... Niles, IL (PRWEB) , ... March 27, 2017 ... ... testing systems, recently received the CE Certificate of Conformity for the Smart System® ... meet or exceed the highest industry standards and specifications such as ANSI, ISO ...
(Date:3/27/2017)... ... March 27, 2017 , ... American Veterinarian™, ... coverage on veterinary medicine, announces the launch of Veterinarian’s Money Digest™, a business ... the April edition of American Veterinarian™. , “We look forward to ...
(Date:3/27/2017)... ... March 27, 2017 , ... Metabolism and hormone ... Women’s Excellence will help patients lose weight and keep it off. , The ... at Women's Excellence will measure BMI, body fat composition, and Calcium and Magnesium ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... and BOSTON , March 27, ... global pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq: ... and commercialization of innovative therapies based upon tetracycline ... of sarecycline for the treatment of moderate to ... endpoints. Sarecycline is a once-daily, oral, narrow spectrum ...
(Date:3/27/2017)... 27, 2017  PhaseRx, Inc. (NASDAQ: PZRX), a ... liver diseases in children, today reported financial results ... December 31, 2016 and provided an update on ... to make progress during the fourth quarter of ... our non-human primate safety study, and with our lead ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... offering. ... The Cell Therapy Manufacturing Market, 2017-2027 report provides an extensive ... and focuses both on contract manufacturers and cell therapy developers ... as viable alternatives to conventional treatment options. ...
Breaking Medicine Technology: